0000899243-20-034280.txt : 20201217 0000899243-20-034280.hdr.sgml : 20201217 20201217160507 ACCESSION NUMBER: 0000899243-20-034280 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201215 FILED AS OF DATE: 20201217 DATE AS OF CHANGE: 20201217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SCHELLER RICHARD H CENTRAL INDEX KEY: 0001214133 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 201396142 MAIL ADDRESS: STREET 1: C/O GENENTECH INC STREET 2: 1 DNA WAY MS 49 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080-4990 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-15 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001214133 SCHELLER RICHARD H C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 1 1 0 0 See Remarks Common Stock 2020-12-15 4 M 0 29277 17.00 A 167704 D Common Stock 2020-12-15 4 S 0 12091 59.806 D 155613 D Common Stock 2020-12-15 4 S 0 19352 60.7329 D 136261 D Stock Option (Right to Buy) 17.00 2020-12-15 4 M 0 29277 0.00 D 2029-06-26 Common Stock 29277 53388 D Represents the weighted average sale price of the shares sold from $59.40 to $60.39 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a securuity holder of the Issuer, full information regarding the number of share sold at each separate price for all transactions as reported in footnotes 1 and 2. Represents the weighted average sale price of the shares sold from $60.40 to $61.17 per share The shares subject to this option vest and become exercisable in 48 equal monthly installments after June 26, 2019, subject to the Reporting Person's continued service to the Issuer through each such date. Chairman of Research and Development /s/ Tara Condon, Attorney-in-Fact 2020-12-17